Cancer metastasis and EGFR signaling is suppressed by Amiodarone-induced Versican V2

Oncotarget

Volumn 6, Issue 40, 2015, Pages 42976-42987

  Lee, Hung Chieh ^a   Su, Mai Yan ^b   Lo, Hao Chan ^b   Wu, Chin Chieh ^c   Hu, Jia Rung ^a   Lo, Dao Ming ^b   Chao, Tsu Yi ^d   Tsai, Huai Jen ^a   Dai, Ming Shen ^c  

^a MACKAY MEDICAL COLLEGE   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Amiodarone; EGFR signaling; Metastasis; Versican

Indexed keywords

AMIODARONE; CETUXIMAB; ISOPROTEIN; PROTEOGLYCAN; TAMOXIFEN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; UVOMORULIN; VASCULOTROPIN RECEPTOR; VERSICAN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL LINE; CANCER GROWTH; CANCER PROGNOSIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; WESTERN BLOTTING; ZEBRA FISH; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; DRUG EFFECTS; FEMALE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE; TUMOR INVASION;

AMIODARONE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; NEOPLASM INVASIVENESS; NEOPLASMS; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VERSICANS;

EID: 84952332397     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5621     Document Type: Article

References (51)

1. Nguyen DX, and Massagué J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007; 8: 341-52.
2. Solnica-Krezel L. Conserved patterns of cell movements during vertebrate gastrulation. Curr Biol. 2005; 15: R213-28.
3. Tucker RP. Neural crest cells: a model for invasive behavior. Int J Biochem Cell Biol. 2004; 36: 173-7.
4. Mercado-Pimentel ME, and Runyan RB. Multiple transforming growth factor-beta isoforms and receptors function during epithelial-mesenchymal cell transformation in the embryonic heart. Cells Tissues Organs. 2007;185: 146-56.
5. Micalizzi DS, Farabaugh SM, and Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010; 15: 117-34.
6. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, and García De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000; 2:84-9.
7. Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M, and Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003; 116: 499-511.
8. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, and Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117: 927-39.
9. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, and Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Natl Cancer Inst. 2008; 100: 672-9.
10. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009; 106: 13820-5.
11. Liotta LA, and Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001; 411: 375-9.
12. Ruoslahti E. Brain extracellular matrix. Glycobiology. 1996;6: 489-92.
13. Rahmani M, Wong BW, Ang L, Cheung CC, Carthy JM, Walinski H, and McManus BM. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol. 2006; 84: 77-92.
14. Ricciardelli C, Sakko AJ, Ween MP, Russell DL, and Horsfall DJ. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 2009; 28: 233-45.
15. Kinsella MG, Bressler SL, and Wight TN. The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr. 2004; 14: 203-34.
16. Rahmani M, McDonald PC, Wong BW, and McManus BM. Transplant vascular disease: role of lipids and proteoglycans. Can J Cardiol. 2004; 20: 58B-65B.
17. Wight TN, and Merrilees MJ. Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res. 2004; 94: 1158-67.
18. Ang LC, Zhang Y, Cao L, Yang BL, Young B, Kiani C, Lee V, Allan K, and Yang BB. Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 domain. J Neuropathol Exp Neurol. 1999; 58: 597-605.
19. Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, and Perris R. The globular domains of PGM/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J. 2004; 18: 779-81.
20. Paris S, Sesboue R, Chauzy C, Maingonnat C, and Delpech B. Hyaluronectin modulation of lung metastasis in nude mice. European Journal of Cancer. 2006; 42: 3253-9.
21. Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley WD, and Horsfall DJ. Formation of hyaluronan-and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem. 2007; 282: 10814-25.
22. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, and Yang B. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res. 2007; 9: R47.
23. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, and Yang BB. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J. 2004; 18: 754-6.
24. Wu YJ, Lapierre D, Wu J, Yee AJ, and Yang BB. The interaction of versican with its binding partners. Cell Res. 2005; 15: 483-94.
25. Du WW, Fang L, Yang X, Sheng W, Yang BL, Seth A, Zhang Y, Yang BB, and Yee AJ. The role of versican in modulating breast cancer cell self-renewal. Mol Cancer Res. 2013;11: 443-55.
26. Heger JJ, Solow EB, Prystowsky EN, and Zipes DP. Plasma and red blood cell concentrations of amiodarone during chronic therapy. Am J Cardiol. 1984; 53: 912-7.
27. Singh BN. Amiodarone: historical development and pharmacologic profile. Am Heart J. 1983; 106: 788-97.
28. Mason JW. Amiodarone. N Engl J Med. 1987; 316: 455-66.
29. Helmy I, Herre JM, Gee G, Sharkey H, Malone P, Sauve MJ, Griffin JC, and Scheinman MM. Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias. J Am Coll Cardiol. 1988; 12: 1015-22.
30. Chen YH, Lee HC, Hsu RJ, Chen TY, Huang YK, Lo HC, Hu SC, Harn HJ, Jeng JR, Sun CK, Lin SZ, and Tsai HJ. The toxic effect of Amiodarone on valve formation in the developing heart of zebrafish embryos. Reprod Toxicol. 2012; 33: 233-44.
31. Schrijver I, Liu W, Brenn T, Furthmayr H, and Francke U. Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. Am J Hum Genet. 1999; 65: 1007-20.
32. El Guerrab A, Zegrour R, Nemlin CC, Vigier F, Cayre A, Penault-Llorca F, Rossignol F, and Bignon YJ. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer. PLoS One. 2011; 6: e25080.
33. Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, Slingerland J, Dumont D, and Yang BB. The Roles of Versican V1 and V2 Isoforms in Cell Proliferation and Apoptosis. Mol Biol Cell. 2005; 16: 1330-40.
34. Pedersen MW, Meltorn M, Damstrup L, and Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol. 2001; 12: 745-60.
35. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer. 2001; 37: S16-22.
36. Margolis BL, Lax I, Kris R, Dombalagian M, Honegger AM, Howk R, Givol D, Ullrich A, and Schlessinger J. All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J Biol Chem. 1989; 264: 10667-71.
37. Walton GM, Chen WS, Rosenfeld MG, and Gill GN. Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. J Biol Chem. 1990; 265: 1750175-4.
38. Tice DA, Biscardi JS, Nickles AL, and Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci U S A. 1999; 96: 1415-20.
39. Mueller KL, Powell K, Madden JM, Eblen ST, and Boerner JL. EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK. Transl Oncol. 2012; 5: 327-34.
40. Sato K. Cellular functions regulated by phosphorylation of EGFR on Tyr845. Int J Mol Sci. 2013; 14: 10761-90.
41. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, and Thomas S, Brugge J, Pelicci PG, Schlessinger J, Pawson T. Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature. 1992; 360: 689-92.
42. Batzer AG, Rotin D, Urena JM, Skolnik EY, and Schlessinger J. Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol. 1994; 14: 5192-201.
43. Hsu JM, Chen CT, Chou CK, Kuo HP, Li LY, Lin CY, Lee HJ, Wang YN, Liu M, Liao HW, Shi B, Lai CC, Bedford MT, et al. Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol. 2011; 13: 174-81.
44. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD, and Horsfall DJ. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res. 2004; 10: 2491-8.
45. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, and Mok SC. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013; 73: 5016-28.
46. Wu Y, Sheng W, Chen L, Dong H, Lee V, Lu F, Wong CS, Lu WY, and Yang BB. Versican V1 isoform induces neuronal differentiation and promotes neurite outgrowth. Mol Biol Cell. 2004; 15: 2093-104.
47. Schmalfeldt M, Bandtlow CE, Dours-Zimmermann MT, Winterhalter KH, and Zimmermann DR. Brain derived versican V2 is a potent inhibitor of axonal growth. J Cell Sci. 2000; 113: 807-16.
48. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002; 14: 617-23.
49. Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK, and Ricciardelli C. Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. Clin Exp Metastasis. 2011; 28: 113-25.
50. Ween MP, Oehler MK, and Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci. 2011; 12: 1009-29.
51. Lim J, and Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development. 2012; 139: 3471-86.